International Standard
ISO 12417-1:2024
Cardiovascular implants and extracorporeal systems — Vascular device-drug combination products — Part 1: General requirements
Reference number
ISO 12417-1:2024
Edition 2
International Standard
Read sample
ISO 12417-1:2024
Published (Edition 2, 2024)

ISO 12417-1:2024

ISO 12417-1:2024
CHF 173
Convert Swiss francs (CHF) to your currency


This document specifies requirements for vascular device-drug combination products (VDDCPs).

With regard to safety, this document outlines requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging and information supplied by the manufacturer.

For implanted products, this document is intended to be used as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants. This document is intended to be used as a supplement to relevant device-specific standards, such as the ISO 25539 series specifying requirements for endovascular devices. Requirements listed in this document also address VDDCPs that are not permanent implants.

NOTE 1        Due to variations in the design of combination products covered by this document and due to the relatively recent development of some of these combination products, acceptable standardized in vitro test results and clinical study results are not always available. As further scientific and clinical data become available, appropriate revision of this document can be necessary.

This document applies to delivery systems or parts of the delivery system that are an integral component of the vascular device and that are drug-covered (e.g. drug-covered balloon catheters and drug-covered guidewires).

This document does not apply to devices whose PMOA provide a conduit for delivery of a drug (e.g. infusion catheters), unless they contain a drug component that is intended to have an ancillary action to the device part (e.g. antimicrobial coated infusion catheter).

This document does not apply to procedures and devices used prior to and following the introduction of the VDDCP (e.g. balloon angioplasty devices) that do not affect the drug-related aspects of the device.

This document does not provide a comprehensive pharmacological evaluation of VDDCPs.

NOTE 2        Some information about the requirements of certain national and regional authorities is given in Annex B.

The connection of absorbable components of VDDCPs (e.g. coatings) with drug-related aspects of the device are addressed in this document. This document does not provide an exhaustive list of the degradation and other time-dependent aspects of absorbable implants and coatings.

NOTE 3        For more information on absorbable coatings, refer to ISO/TS 17137 and ASTM F3036-13.

This document does not address issues associated with viable or non-viable biological materials such as tissues, cells or proteins.

This document does not address issues associated with active surgical implants (i.e. implants that require power not generated by the human body or gravity).

General information

  •  : Published
     : 2024-02
    : International Standard published [60.60]
  •  : 2
     : 48
  • ISO/TC 150/SC 2
  • RSS updates

Got a question?

Check out our Help and Support

Check out our FAQs

Customer care
+41 22 749 08 88

Opening hours:
Monday to Friday - 09:00-12:00, 14:00-17:00 (UTC+1)